UK Study Shows rifaximin-α (XIFAXAN® 550mg / TARGAXAN® 550mg) for Hepatic Encephalopathy May Reduce Costs to Healthcare Systems

UK Study Shows rifaximin-α (XIFAXAN® 550mg / TARGAXAN® 550mg) for Hepatic Encephalopathy May Reduce Costs to Healthcare Systems

Norgine B.V. today presented new UK real world data, IMPRESS, that show rifaximin-α for the treatment of hepatic encephalopathy could reduce costs related to non-elective hospital admissions, critical care bed occupancy, emergency room visits and 30-day emergency re-admissions.[1] Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease and is associated with increased hospitalisations.[2]

These data were presented at the International Society for Pharmacoeconomics and Outcomes Research Annual European Congress 2016, Austria.

IMPRESS is a retrospective observational study that demonstrates hospital resource use was significantly lower in the post-rifaximin-α initiation period, compared with the pre-rifaximin-α initiation period. Estimated cost reductions* per patient were;[1]

£2,031 in non-elective hospitalisations
£9,117 in critical care bed days
£121 in emergency room visits
£1,518 in 30-day emergency re-admissions

Peter Martin, Chief Operating Officer at Norgine said; “These data reinforce the value that XIFAXAN® 550mg / TARGAXAN® 550mg can bring to patients suffering from hepatic encephalopathy and to healthcare systems overall. By using XIFAXAN® 550mg / TARGAXAN® 550mg which reduces the recurrence of episodes of hepatic encephalopathy, hospitals can decrease the level of resources used. This in turn means lower costs for hospital admissions and bed occupancy.”

Hepatic encephalopathy affects around 10,000 patients in the UK.[3]

XIFAXAN® 550mg / TARGAXAN® 550mg / TIXTELLER® 550mg is reimbursed through healthcare systems in Australia, England and Wales, Germany, Ireland, Italy, Luxembourg, New Zealand, Norway, Scotland, Sweden and Switzerland.

* Treatment costs were not included.

View the full press release on http://www.norgine.com

1. Hudson. M. et al. The impact of rifaximin-α on non-elective hospital admission and attendance costs in UK patients with hepatic encephalopathy. Abstract 67307. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress,
29 October-2 November 2016; Vienna, Austria.

2. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014. 109. 1757-63.

3. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. Journal of Hepatology 49 (2008) 732-738.

Media Contacts:
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44(0)1895-453607

SOURCE Norgine B.V.

LONDON, October 31, 2016 /PRNewswire/

http://www.prnewswire.co.uk/

 

October 31, 2016 / Pharma News